28.20
+1.24(+4.60%)
Currency In USD
| Previous Close | 26.96 |
| Open | 26.94 |
| Day High | 28.45 |
| Day Low | 26.59 |
| 52-Week High | 51.61 |
| 52-Week Low | 18.53 |
| Volume | 1.6M |
| Average Volume | 1.47M |
| Market Cap | 1.8B |
| PE | -7.86 |
| EPS | -3.59 |
| Moving Average 50 Days | 22.78 |
| Moving Average 200 Days | 27.2 |
| Change | 1.24 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $2,452.17 as of September 29, 2025 at a share price of $28.2. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $1,351.22 as of September 29, 2025 at a share price of $28.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Aug 08, 2025 8:05 PM GMT
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 04, 2025 8:05 PM GMT
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
GlobeNewswire Inc.
Jun 03, 2025 10:30 AM GMT
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases,